MarginsXMarginsX
Home › Markets › Health Care › ABSI

Absci Corporation (ABSI)

ABSI trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.47
-11.54% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$2.8M
-38.2% on 2024
Net income · 2025
-$115.2M
-4113.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/0001672688-26-000068-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABSI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2021
SEC CIK0001672688
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$2.8M
Net income-$115.2M
Operating income-$120.3M
Net margin-4113.7%
Operating margin-4297.0%
Revenue growth-38.2%
Cash$20.0M
Total assets$216.3M
P/E (computed)Net income was not positive
P/S (computed)461.2×

Warning signs

Cash runway
1.4 months
$13.4M cash at September 30, 2026
Share count, 1 year
+14.9%
2025-10-31 to 2026-10-30 · +85.9% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$801K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$13.4M cash; operating cash flow -$28.1M a quarter.Report 2026-09-30
Shares outstanding172,745,810 (2026-10-30); 150,371,531 a year earlier; 92,938,477 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Jose, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $933K, sold $132K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$304K-$33.3M-$29.5M$13.4M$61K$1.5M10-Q 2026-11-12
Q2 2026
2026-06-30
$318K-$33.2M-$27.6M$107.9M$150K$1.6M10-Q 2026-08-11
Q1 2026
2026-03-31
$215K-$29.6M-$26.3M$8.6M$413K$1.8M10-Q 2026-05-07
Q4 2025
2025-12-31
$650K-$29.6M-$29.2M$20.0M$873K$2.8M10-K 2026-03-24
Q3 2025
2025-09-30
$378K-$28.7M-$25.0M$9.5M$1.3M$2.8M10-Q 2026-11-12
Q2 2025
2025-06-30
$593K-$30.6M-$16.9M$38.0M$2.0M$4.1M10-Q 2026-08-11
Q1 2025
2025-03-31
$1.2M-$26.3M-$21.8M$47.0M$2.5M$4.8M10-Q 2026-05-07
Q4 2024
2024-12-31
$665K-$29.0M-$17.0M$41.2M$4.0M$4.5M10-K 2025-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-12
Latest annual report10-K2026-03-24
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 364 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-16.9%
1 month-7.1%
3 months-10.7%
Year to date+142.1%
1 year+220.1%
From 52-week high-30.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M
ICLRICON plc$191.40-1.67%$14.7B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
INCYIncyte Corp.$120.27-0.58%$24.5B
IQVIQVIA Holdings Inc.$264.73-0.15%$43.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier